Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 5/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | NPC1 | O15118 | 4/20 | 0.46 |
| ▸ | RAB9A | P51151 | 4/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | BTK | Q06187 | 1/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.44 |
| ▸ | CCR1 | P32246 | 2/20 | 0.44 |
| ▸ | CCR5 | P51681 | 2/20 | 0.44 |
| ▸ | CCR8 | P51685 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | METAP1 | P53582 | 1/20 | 0.44 |
| ▸ | BLM | P54132 | 1/20 | 0.44 |
| ▸ | DOHH | Q9BU89 | 1/20 | 0.44 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.44 |
| ▸ | GSK3B | P49841 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5709792 | 0.82 | NOTUM (0.52) | CHEK1LMNAKDM4EALDH1A1NPC1 | |
| SCHEMBL29664837 | 0.82 | NOTUM (0.52) | CHEK1LMNAKDM4EALDH1A1NPC1 | |
| SCHEMBL27196408 | 0.76 | KDM4E (0.54) | CHEK1LMNAKDM4EALDH1A1NPC1 | |
| SCHEMBL13611987 | 0.74 | LMNA (0.54) | LMNAKDM4EALDH1A1NPC1RAB9A | |
| SCHEMBL28600777 | 0.73 | TAS2R38 (0.57) | CHEK1LMNAKDM4EALDH1A1NPC1 | |
| SCHEMBL20510086 | 0.72 | KDM4E (0.50) | CHEK1LMNAKDM4EALDH1A1NPC1 | |
| SCHEMBL1988750 | 0.72 | KDM4E (0.58) | CHEK1LMNAKDM4EALDH1A1NPC1 | |
| SCHEMBL24672383 | 0.72 | NOTUM (0.44) | BTKGSK3BCDK5XDHNPY5R | |
| SCHEMBL1456454 | 0.72 | KDM4E (0.62) | LMNAKDM4EALDH1A1NPC1RAB9A | |
| SCHEMBL29624537 | 0.72 | KDM4E (0.62) | LMNAKDM4EALDH1A1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190241569-A1 | 3-(ARYL OR HETEROARYL) METHYLENEINDOLIN-2-ONE DERIVATIVES AS INHIBITORS OF CANCER STEM CELL PATHWAY KINASES FOR THE TREATMENT OF CANCER | BOSTON BIOMEDICAL INC (US) | 2019-08-08 | — | — | US | claimed |
| US-20160031888-A1 | 3-(ARYL OR HETEROARYL) METHYLENEINDOLIN-2-ONE DERIVATIVES AS INHIBITORS OF CANCER STEM CELL PATHWAY KINASES FOR THE TREATMENT OF CANCER | BOSTON BIOMEDICAL, INC. (US) | 2016-02-04 | — | — | US | claimed |
| EP-2970206-A1 | 3-(ARYL OR HETEROARYL) METHYLENEINDOLIN-2-ONE DERIVATIVES AS INHIBITORS OF CANCER STEM CELL PATHWAY KINASES FOR THE TREATMENT OF CANCER | Boston Biomedical, Inc. (US) | 2016-01-20 | — | — | EP | claimed |
| WO-2014160401-A1 | 3-(ARYL OR HETEROARYL) METHYLENEINDOLIN-2-ONE DERIVATIVES AS INHIBITORS OF CANCER STEM CELL PATHWAY KINASES FOR THE TREATMENT OF CANCER | BOSTON BIOMEDICAL, INC. (US) | 2014-10-02 | — | — | WO | claimed |
| US-20260069589-A1 | TREATMENT FOR OBESITY | 1GLOBE BIOMEDICAL CO LTD (CN) | 2026-03-12 | — | — | US | disclosed |
| US-20250275960-A1 | TREATMENT FOR NON-ALCOHOLIC FATTY LIVER DISEASE | 1GLOBE BIOMEDICAL CO LTD (CN) | 2025-09-04 | — | — | US | disclosed |
| US-12390460-B2 | Treatment for obesity | 1GLOBE BIOMEDICAL CO., LTD. (CN) | 2025-08-19 | — | — | US | disclosed |
| US-12318381-B2 | Treatment for non-alcoholic fatty liver disease | 1GLOBE BIOMEDICAL CO., LTD. (CN) | 2025-06-03 | — | — | US | disclosed |
| CN-117224541-A | Treatment of obesity | 北京强新生物科技有限公司 | 2023-12-15 | — | — | CN | disclosed |
| CN-112955143-B | Treatment of non-alcoholic fatty liver disease | 北京强新生物科技有限公司 | 2023-10-13 | — | — | CN | disclosed |
| CN-112996507-B | Treatment of obesity | 北京强新生物科技有限公司 | 2023-09-05 | — | — | CN | disclosed |
| WO-2022072645-A3 | PYRROLOPYROLIDINONE AND PYRROLOAZEPINONE DERIVATIVES FOR USE IN TREATING CANCER | SCORPION THERAPEUTICS, INC. (US) | 2022-10-20 | — | — | WO | disclosed |
| EP-1507549-A4 | DRUG THERAPY FOR CELIAC SPRUE | UNIV LELAND STANFORD JUNIOR (US) | 2009-07-01 | — | — | EP | disclosed |
| WO-2008147713-A1 | WNT SIGNALING INHIBITORS, AND METHODS FOR MAKING AND USING THEM | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2008-12-04 | — | — | WO | disclosed |
| US-20060035838-A1 | Drug therapy for celiac sprue | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2006-02-16 | — | — | US | disclosed |
| EP-1507549-A2 | DRUG THERAPY FOR CELIAC SPRUE | The Board of Trustees of The Leland Stanford Junior University (US) | 2005-02-23 | — | — | EP | disclosed |
| WO-2003096979-A2 | DRUG THERAPY FOR CELIAC SPRUE | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2003-11-27 | — | — | WO | disclosed |
| EP-0387595-B1 | Heterocyclic compounds | BAYER AG (DE) | 1994-05-25 | — | — | EP | disclosed |
| US-5258511-A | Pyrazoloazepinones and methods of using such pyrazoloazepinones to dye synthetic fibers and to pigment pastes, paints, printing inks, colored paper and colored macromolecular substances | BAYER AKTIENGESELLSCHAFT (DE) | 1993-11-02 | — | — | US | disclosed |
| EP-0387595-A2 | Heterocyclic compounds | BAYER AG (DE) | 1990-09-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12318381-B2 | Treatment for non-alcoholic fatty liver disease | FABP1, CPT1A, LIPC | CHEK1 4656/4885LMNA 1898/4885KDM4E 1833/4885 |
| US-12390460-B2 | Treatment for obesity | GPR119, MC4R, FABP4 | CHEK1 4789/4885LMNA 3862/4885KDM4E 1253/4885 |
| US-20190241569-A1 | 3-(ARYL OR HETEROARYL) METHYLENEINDOLIN-2-ONE DERIVATIVES AS INHIBITORS OF CANCER STEM CELL PATHWAY KINASES FOR THE TREATMENT OF CANCER | MAP3K2, MAP3K1, MAP3K3 | CHEK1 71/4885LMNA 2995/4885KDM4E 1394/4885 |
| US-20260069589-A1 | TREATMENT FOR OBESITY | GPR119, NR3C2, HCRTR2 | CHEK1 4528/4885LMNA 2526/4885KDM4E 3002/4885 |
| US-20060035838-A1 | Drug therapy for celiac sprue | SI, TMPRSS15, DNPEP | CHEK1 2915/4885LMNA 4799/4885KDM4E 2859/4885 |
| US-20250275960-A1 | TREATMENT FOR NON-ALCOHOLIC FATTY LIVER DISEASE | FABP1, CPT1A, LIPC | CHEK1 4656/4885LMNA 1898/4885KDM4E 1833/4885 |
| US-20160031888-A1 | 3-(ARYL OR HETEROARYL) METHYLENEINDOLIN-2-ONE DERIVATIVES AS INHIBITORS OF CANCER STEM CELL PATHWAY KINASES FOR THE TREATMENT OF CANCER | MAP3K19, MAP3K2, MAP3K3 | CHEK1 74/4885LMNA 3053/4885KDM4E 788/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.